<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02831504</url>
  </required_header>
  <id_info>
    <org_study_id>7491</org_study_id>
    <nct_id>NCT02831504</nct_id>
  </id_info>
  <brief_title>PhenoDM1 (Myotonic Dystrophy Type 1 Natural History Study)</brief_title>
  <acronym>PhenoDM1</acronym>
  <official_title>Myotonic Dystrophy Type 1 (DM1) Deep Phenotyping to Improve Delivery of Personalized Medicine and Assist in the Planning, Design and Recruitment of Clinical Trials</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Newcastle-upon-Tyne Hospitals NHS Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Newcastle-upon-Tyne Hospitals NHS Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      PhenoDM1 will use patient reported outcomes to assess levels of pain, fatigue and quality of&#xD;
      life in this cohort. Clinical and functional outcomes will look at muscle wasting and levels&#xD;
      of myotonia. DNA, RNA, serum and CSF samples will be taken from all patients so that&#xD;
      additional genetic and molecular biomarker analysis can be carried out. A subset of patients&#xD;
      will undergo detailed sleep studies along with skeletal muscle MRI of the lower limbs. This&#xD;
      study will complement the work of other groups currently looking at myotonic dystrophy type 1&#xD;
      using the same outcomes and measures where possible.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Myotonic Dystrophy type I (DM1) is the most common form of adult muscular dystrophy,&#xD;
      affecting 1 in 8000 individuals. It is an autosomal dominant disorder with multisystemic&#xD;
      involvement of multiple organs and tissues, namely brain, heart, endocrine system, eyes and&#xD;
      both smooth and skeletal muscles. It results from the CTG expansion of an untranslated region&#xD;
      3' terminal of the DMPK gene which causes a disturbance of the RNA metabolism, in particular&#xD;
      defective splicing of various pre-mRNAs such as the muscular chloride channel (causing&#xD;
      myotonia), the insulin receptor (causing diabetes) and others. We will carry out an in-depth&#xD;
      characterisation of 400 adult DM1 patients identified from local clinical populations across&#xD;
      England and through the national DM Registry. Over a two year period we will take&#xD;
      measurements 12 months apart to address specific symptoms that cause major quality of life&#xD;
      impairment including muscle weakness, myotonia, excessive daytime sleepiness and cognitive&#xD;
      impairment. DNA samples will be collected in order to determine the CTG repeat length and&#xD;
      serum samples for biomarker identification. We will carry out muscle MRI and sleep studies in&#xD;
      a subset of 50 patients. The implemented measures will capitalise on the efforts of previous&#xD;
      cohort studies ensuring that all measures are comparable with existing datasets.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 2015</start_date>
  <completion_date type="Actual">October 31, 2018</completion_date>
  <primary_completion_date type="Actual">October 31, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Strength and function</measure>
    <time_frame>9-12 months</time_frame>
    <description>These assessments include:&#xD;
Manual Muscle Testing&#xD;
Quantitative Muscle Testing (Hand Held Myometry, Hand-Grip Dynamometry)&#xD;
Pulmonary function testing (FVC and MIP)&#xD;
Functional evaluations (Nine Hole Peg Test, Six Minute Walk Test, 30 Seconds Sit and Stand Test, Timed 10-Meter Walk Test, Scale for Assessment and Rating of Ataxia Scale, Accelerometry Assessment)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cognitive assessment</measure>
    <time_frame>9-12 months</time_frame>
    <description>These questionnaires include:&#xD;
Mini-Mental State Examination (MMS)&#xD;
Trail Making Test (TMT)&#xD;
Apathy Evaluation Scale (AES)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life using patient-reported outcomes</measure>
    <time_frame>9-12 months</time_frame>
    <description>These questionnaires include:&#xD;
Individualised Neuromuscular Quality Of Life (InQoL)&#xD;
Myotonic Dystrophy Health Index (MDHI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatigue and Daytime Sleepiness assessment using patient-reported outcomes</measure>
    <time_frame>9-12 months</time_frame>
    <description>These questionnaires include:&#xD;
Checklist Individual Strength&#xD;
Epworth Sleepiness Scale&#xD;
Fatigue and Daytime Sleepiness Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain assessment using patient-reported outcomes</measure>
    <time_frame>9-12 months</time_frame>
    <description>These questionnaires include:&#xD;
McGill questionnaire&#xD;
IVR Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood and Urine collection for genetic and molecular biomarker analysis</measure>
    <time_frame>9-12 months</time_frame>
    <description>Collection of: RNA, DNA, Serum and Urine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood collection for Glycated Haemoglobin (HbA1c), Thyroid hormones, Androgens (in males only) analysis</measure>
    <time_frame>9-12 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Sleep Study</measure>
    <time_frame>9-12 months</time_frame>
    <description>Assessment by polysomnography and maintenance of wakefulness test (MWT)</description>
  </other_outcome>
  <other_outcome>
    <measure>Skeletal Muscle MRI of the lower extremities</measure>
    <time_frame>9-12 months</time_frame>
    <description>Three imaging scans will be acquired of the lower extremities: T1-weighted images, TIRM images and Dixon images.</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">213</enrollment>
  <condition>Myotonic Dystrophy Type 1</condition>
  <arm_group>
    <arm_group_label>Myotonic Dystrophy type 1 (DM1) patients</arm_group_label>
    <description>Natural History Study</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      All blood and urine will be processed and stored in Newcastle Biobank for Research of&#xD;
      Neuromuscular Disorders (Newcastle and North Tyneside 1 -REF/08/H0906/28).&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Inclusion criteria will be limited to those over 18 years of age, with a genetic&#xD;
        confirmation of DM1 who are able to provide informed consent. This unrestrictive approach&#xD;
        will enable assessment of a true cross-section of the population, including those with&#xD;
        congenital, childhood and adult onset. Two substudies will be open to a subset of patients,&#xD;
        one assessing muscle through MRI and on focussing on sleep and fatigue. Additional&#xD;
        restrictions may be in place to ensure the safety of the participants during these studies.&#xD;
&#xD;
        Informed consent will be obtained from all patients, including detailed patient&#xD;
        information. Sharing and storage of data and samples will be discussed in this information&#xD;
        and covered appropriately in the consent.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Main Inclusion Criteria&#xD;
&#xD;
          1. 18 years of age or over&#xD;
&#xD;
          2. Genetic confirmation of Myotonic Dystrophy Type 1&#xD;
&#xD;
          3. Able to consent and willing to participate throughout the duration of the study.&#xD;
&#xD;
        Additional Inclusion Criteria for MRI study:&#xD;
&#xD;
          1. Aged between 18 and 55 years&#xD;
&#xD;
          2. Ambulant or ambulant-assisted&#xD;
&#xD;
        Additional Inclusion Criteria for sleep study:&#xD;
&#xD;
        1. Aged between 18 and 55 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Main Exclusion Criteria&#xD;
&#xD;
          1. Inability to give informed consent&#xD;
&#xD;
          2. If the clinician presumes that the patient will not be able to perform any of the&#xD;
             motor function tests involved (Six Minute Walk Test, 30 Seconds Sit and Stand Test,&#xD;
             Timed 10-Meter Walk Test)&#xD;
&#xD;
          3. Inability to perform the cardiac and pulmonary assessments&#xD;
&#xD;
        Additional Exclusion Criteria for MRI study:&#xD;
&#xD;
        1. Pacemaker, ICD or non-MRI-compatible prosthetic material.&#xD;
&#xD;
        Additional Exclusion Criteria for sleep study:&#xD;
&#xD;
          1. ventilated patients&#xD;
&#xD;
          2. patients medicated with stimulants, including Modafinil&#xD;
&#xD;
          3. patients medicated with benzodiazepines or antidepressants&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hanns Lochmuller, MD, FAAN</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Newcastle Upon-Tyne</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chris Turner, FRCP, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Hospital for Neurology and Neurosurgery</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Newcastle-upon-Tyne Hospitals NHS Trust</name>
      <address>
        <city>Newcastle Upon Tyne</city>
        <state>Tyne And Wear</state>
        <zip>NE1 4LP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University College London Hospitals NHS Foundation Trust, National Hospital for Neurology and Neurosurgery</name>
      <address>
        <city>London</city>
        <zip>WC1N 3BG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 22, 2016</study_first_submitted>
  <study_first_submitted_qc>July 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 13, 2016</study_first_posted>
  <last_update_submitted>April 12, 2021</last_update_submitted>
  <last_update_submitted_qc>April 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Myotonic Dystrophy type 1</keyword>
  <keyword>DM1</keyword>
  <keyword>Muscular Dystrophy</keyword>
  <keyword>Neuromuscular Diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myotonic Dystrophy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

